| Name | Title | Contact Details |
|---|
Sklar Corporation is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carol Cole Company is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We focus on improving the lives of our patients with collaborative care, breakthrough research and by training tomorrow`s physicians. We are University of Minnesota Physicians, the multi-specialty group practice for the University of Minnesota Medical School faculty. As clinicians, we practice in primary care and over 100 specialty and subspecialty areas. As educators, we apply our state-of-the-art knowledge to teach and mentor future physicians. As researchers, we address critical medical problems, then translate our research findings into novel therapies to benefit patients. Our physicians practice academic medicine in an environment of inquiry and education. They work closely with other specialists across disciplines so that our patients receive comprehensive, well-coordinated care tied directly to innovations developed by our research. At UMPhysicians, every employee and physician has a role to play in fostering a culture of integrity and demonstrating our values of Service, Innovation and Respect.
Concorde Medical Group PLLC is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.